
Franco-Austrian drugmaker Valneva's vaccine candidate against chikungunya – a mosquito-borne virus that causes occasional outbreaks across the world – has revealed promising results in a wide-ranging new trial.
While the results of a study released this week have been hailed as good news in the fight against chikungunya, the trial was carried out on people in the United States – where the virus is extremely rare – experts say more research is needed.